The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer
Abstract Background Postoperative chemotherapy is an essential treatment in locally advanced colon cancer, however, effective biomarkers for predicting patients who will benefit from this therapy are lacking. This study aims to explore the clinical value of protein arginine methyltransferase 5 (PRMT...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14161-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849713788484321280 |
|---|---|
| author | Lu Lu Huan Li Hongfang Yin Feng Wang Xiaowen Sun Yanyun Chang Yuling Sheng Qi Liu Yifan Peng Changzheng Du |
| author_facet | Lu Lu Huan Li Hongfang Yin Feng Wang Xiaowen Sun Yanyun Chang Yuling Sheng Qi Liu Yifan Peng Changzheng Du |
| author_sort | Lu Lu |
| collection | DOAJ |
| description | Abstract Background Postoperative chemotherapy is an essential treatment in locally advanced colon cancer, however, effective biomarkers for predicting patients who will benefit from this therapy are lacking. This study aims to explore the clinical value of protein arginine methyltransferase 5 (PRMT5) in guiding adjuvant chemotherapy in patients with colon cancer. Methods PRMT5 expression was determined via immunohistochemistry (IHC) in tumor and paratumor samples from 199 colon cancer patients who underwent radical surgery. The correlation between PRMT5 expression and clinicopathological parameters, as well as clinical outcomes, was subsequently investigated. Results The protein expression levels of PRMT5 were significantly elevated in colon cancer tissues compared to paratumor tissues (P < 0.01). However, the expression of PRMT5 in colon cancer did not show a significant association with various clinicopathological parameters, including sex, age, tumor location, histological differentiation, TNM stage, vascular invasion, or microsatellite status. Notably, a strong correlation was observed between PRMT5 expression and adjuvant therapeutic outcomes: patients with high PRMT5 expression exhibited a lower 5-year disease-free survival (DFS) rate compared to those with low PRMT5 expression within the chemotherapy group (50% vs. 67.2%, P = 0.039). In contrast, PRMT5 expression did not correlate with clinical outcomes in the non-chemotherapy group. Furthermore, multivariate analysis indicated that PRMT5 expression, along with N stage and microsatellite status, served as independent risk factors for 5-year DFS in patients undergoing adjuvant chemotherapy. Conclusion This study highlights PRMT5 as a prognostic marker for adjuvant chemotherapy in patients with colon cancer. The findings suggest that PRMT5 expression may serve as an important predictor of therapeutic outcomes, providing valuable insights for clinical decision-making and personalized treatment strategies. |
| format | Article |
| id | doaj-art-d7c8d70a78d54cbf8e21bc646f43e18f |
| institution | DOAJ |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-d7c8d70a78d54cbf8e21bc646f43e18f2025-08-20T03:13:53ZengBMCBMC Cancer1471-24072025-04-012511910.1186/s12885-025-14161-5The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancerLu Lu0Huan Li1Hongfang Yin2Feng Wang3Xiaowen Sun4Yanyun Chang5Yuling Sheng6Qi Liu7Yifan Peng8Changzheng Du9Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua UniversityPathology Department, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua UniversityPathology Department, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua UniversityBeijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua UniversityBeijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua UniversityBeijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua UniversitySchool of Medicine, Southern University of Science and Technology (SUSTech)School of Medicine, Southern University of Science and Technology (SUSTech)Department of Unit III & Ostomy Service, Gastrointestinal Cancer Center, Peking University Cancer Hospital & InstituteCancer Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua UniversityAbstract Background Postoperative chemotherapy is an essential treatment in locally advanced colon cancer, however, effective biomarkers for predicting patients who will benefit from this therapy are lacking. This study aims to explore the clinical value of protein arginine methyltransferase 5 (PRMT5) in guiding adjuvant chemotherapy in patients with colon cancer. Methods PRMT5 expression was determined via immunohistochemistry (IHC) in tumor and paratumor samples from 199 colon cancer patients who underwent radical surgery. The correlation between PRMT5 expression and clinicopathological parameters, as well as clinical outcomes, was subsequently investigated. Results The protein expression levels of PRMT5 were significantly elevated in colon cancer tissues compared to paratumor tissues (P < 0.01). However, the expression of PRMT5 in colon cancer did not show a significant association with various clinicopathological parameters, including sex, age, tumor location, histological differentiation, TNM stage, vascular invasion, or microsatellite status. Notably, a strong correlation was observed between PRMT5 expression and adjuvant therapeutic outcomes: patients with high PRMT5 expression exhibited a lower 5-year disease-free survival (DFS) rate compared to those with low PRMT5 expression within the chemotherapy group (50% vs. 67.2%, P = 0.039). In contrast, PRMT5 expression did not correlate with clinical outcomes in the non-chemotherapy group. Furthermore, multivariate analysis indicated that PRMT5 expression, along with N stage and microsatellite status, served as independent risk factors for 5-year DFS in patients undergoing adjuvant chemotherapy. Conclusion This study highlights PRMT5 as a prognostic marker for adjuvant chemotherapy in patients with colon cancer. The findings suggest that PRMT5 expression may serve as an important predictor of therapeutic outcomes, providing valuable insights for clinical decision-making and personalized treatment strategies.https://doi.org/10.1186/s12885-025-14161-5PRMT5Colon cancerAdjuvant chemotherapy |
| spellingShingle | Lu Lu Huan Li Hongfang Yin Feng Wang Xiaowen Sun Yanyun Chang Yuling Sheng Qi Liu Yifan Peng Changzheng Du The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer BMC Cancer PRMT5 Colon cancer Adjuvant chemotherapy |
| title | The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer |
| title_full | The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer |
| title_fullStr | The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer |
| title_full_unstemmed | The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer |
| title_short | The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer |
| title_sort | expression of prmt5 is associated with postoperative chemotherapeutic outcome in colon cancer |
| topic | PRMT5 Colon cancer Adjuvant chemotherapy |
| url | https://doi.org/10.1186/s12885-025-14161-5 |
| work_keys_str_mv | AT lulu theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT huanli theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT hongfangyin theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT fengwang theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT xiaowensun theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT yanyunchang theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT yulingsheng theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT qiliu theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT yifanpeng theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT changzhengdu theexpressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT lulu expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT huanli expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT hongfangyin expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT fengwang expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT xiaowensun expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT yanyunchang expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT yulingsheng expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT qiliu expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT yifanpeng expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer AT changzhengdu expressionofprmt5isassociatedwithpostoperativechemotherapeuticoutcomeincoloncancer |